Niagen Bioscience, Inc. (NASDAQ:NAGE) Stock Has Consensus Target Price of $10.33

Niagen Bioscience, Inc. (NASDAQ:NAGE) has received an average rating of “Buy” from the five brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $10.33.

Several equities analysts recently commented on the company. Freedom Capital upgraded Niagen Bioscience to a “strong-buy” rating in a research note on Monday, July 6th. Roth Capital reiterated a “buy” rating on shares of Niagen Bioscience in a report on Wednesday, August 5th. HC Wainwright reiterated a “buy” rating on shares of Niagen Bioscience in a report on Wednesday, July 1st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Niagen Bioscience in a research report on Thursday, October 15th.

Institutional Investors Weigh In On Niagen Bioscience

Large investors have recently added to or reduced their stakes in the company. Gamco Investors INC. ET AL increased its stake in Niagen Bioscience by 2.5% during the 1st quarter. Gamco Investors INC. ET AL now owns 165,000 shares of the company’s stock worth $728,000 after buying an additional 4,000 shares during the period. Teton Advisors LLC boosted its position in Niagen Bioscience by 20.0% in the 1st quarter. Teton Advisors LLC now owns 30,000 shares of the company’s stock valued at $132,000 after buying an additional 5,000 shares during the last quarter. Silverberg Bernstein Capital Management LLC boosted its position in Niagen Bioscience by 5.3% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 138,102 shares of the company’s stock valued at $609,000 after buying an additional 6,940 shares during the last quarter. Gabelli Funds LLC boosted its position in Niagen Bioscience by 5.2% in the 1st quarter. Gabelli Funds LLC now owns 214,685 shares of the company’s stock valued at $947,000 after buying an additional 10,685 shares during the last quarter. Finally, Stoneridge Investment Partners LLC acquired a new stake in shares of Niagen Bioscience during the second quarter valued at about $49,000. 15.41% of the stock is owned by institutional investors and hedge funds.

Niagen Bioscience Price Performance

NASDAQ:NAGE opened at $2.47 on Monday. The firm has a market cap of $196.71 million, a PE ratio of 15.69 and a beta of 2.02. The firm has a 50 day simple moving average of $2.95 and a 200-day simple moving average of $3.48. Niagen Bioscience has a 1-year low of $2.42 and a 1-year high of $7.95.

Niagen Bioscience (NASDAQ:NAGE) last announced its earnings results on Tuesday, August 4th. The company reported $0.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.01. Niagen Bioscience had a net margin of 12.39% and a return on equity of 17.95%. The firm had revenue of $29.78 million for the quarter, compared to analyst estimates of $29.95 million. As a group, sell-side analysts expect that Niagen Bioscience will post 0.10 earnings per share for the current fiscal year.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a life sciences company focused on products and technologies designed to support healthy aging and cellular health. The company’s principal technology is nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in cellular energy production and other biological processes.

The company develops and commercializes NIAGEN-branded NR ingredients for use in dietary supplements, functional foods and beverages, and other consumer health products.